UBS Maintains Buy on Cardinal Health, Raises Price Target to $295

UBS analyst Kevin Caliendo has maintained a Buy rating on Cardinal Health (NYSE: CAH) and increased the price target from $280 to $295. This adjustment reflects a positive outlook for the company's stock performance.